Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor

Explore clinical trials studying Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor trial results

Completed

Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex

NCT01323465

Conditions: Chemically-Induced Disorders, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, +4 more
Locations: Guy's Drug Research Unit, Quintiles Ltd. London, United Kingdom

View Trial Details

Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor

Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor trial results

Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex

Related conditions